CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression

被引:83
|
作者
Reynes, J
Portales, P
Segondy, M
Baillat, V
André, P
Avinens, O
Picot, MC
Clot, J
Eliaou, JF
Corbeau, P
机构
[1] Hop St Eloi, Immunol Lab, F-34295 Montpellier 5, France
[2] Hop St Eloi, Virol Lab, F-34295 Montpellier, France
[3] Hop Gui De Chauliac, Serv Malad Infect & Trop, Montpellier, France
[4] Hop Arnaud Villeneuve, Dept Med Informat, Montpellier, France
[5] Inst Genet Humaine, Montpellier, France
关键词
AIDS/HIV; CCR5; CD4 cell slope; chemokine receptor; long-term non-progressor; prognostic factor; T lymphocytes;
D O I
10.1097/00002030-200109070-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective and design: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. Methods: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. Results: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomtic and non-treated, we observed a correlation between CCR5 density on HLA-DR-CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). Conclusion: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 50 条
  • [31] Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity
    Xiao, XD
    Phogat, S
    Shu, Y
    Phogat, A
    Chow, YH
    Wei, OL
    Goldstein, H
    Broder, CC
    Dimitrov, DS
    VACCINE, 2003, 21 (27-30) : 4275 - 4284
  • [32] HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
    Pfaff, Jennifer M.
    Wilen, Craig B.
    Harrison, Jessamina E.
    Demarest, James F.
    Lee, Benhur
    Doms, Robert W.
    Tilton, John C.
    JOURNAL OF VIROLOGY, 2010, 84 (13) : 6505 - 6514
  • [33] Concordance of CCR5 Genotypes that Influence Cell-Mediated Immunity and HIV-1 Disease Progression Rates
    Catano, Gabriel
    Chykarenko, Zoya A.
    Mangano, Andrea
    Anaya, J-M
    He, Weijing
    Smith, Alison
    Bologna, Rosa
    Sen, Luisa
    Clark, Robert A.
    Lloyd, Andrew
    Shostakovich-Koretskaya, Ludmila
    Ahuja, Sunil K.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (02): : 263 - 272
  • [34] Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
    Gong, WH
    Howard, OMZ
    Turpin, JA
    Grimm, MC
    Ueda, H
    Gray, PW
    Raport, CJ
    Oppenheim, JJ
    Wang, JM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (08) : 4289 - 4292
  • [35] Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression
    Smith, MW
    Dean, M
    Carrington, M
    Winkler, C
    Huttley, GA
    Lomb, DA
    Goedert, JJ
    OBrien, TR
    Jacobson, LP
    Kaslow, R
    Buchbinder, S
    Vittinghoff, E
    Vlahov, D
    Hoots, K
    Hilgartner, MW
    OBrien, SJ
    SCIENCE, 1997, 277 (5328) : 959 - 965
  • [36] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [37] Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection
    Browning, J
    Horner, JW
    Pettoello-Mantovani, M
    Raker, C
    Yurasov, S
    DePinho, RA
    Goldstein, H
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) : 14637 - 14641
  • [38] Adverse effect of the CCR5 promoter-2459A allele on HIV-1 disease progression
    Knudsen, TB
    Kristiansen, TB
    Katzenstein, TL
    Eugen-Olsen, J
    JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (03) : 441 - 444
  • [39] Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance
    Anderson, J
    Banerjea, A
    Akkina, R
    OLIGONUCLEOTIDES, 2003, 13 (05) : 303 - 312
  • [40] Localization of CD4 and CCR5 in living cells
    Steffens, CM
    Hope, TJ
    JOURNAL OF VIROLOGY, 2003, 77 (08) : 4985 - 4991